Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD19-positive Relapsed or Refractory B-cell Malignancies”

43 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 43 results

Very early researchLooking for participantsNCT06092047
What this trial is testing

UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies.

Who this might be right for
CD19-positive Relapsed or Refractory B-cell Malignancies
PersonGen BioTherapeutics (Suzhou) Co., Ltd. 10
Early research (Phase 1)WithdrawnNCT03605589
What this trial is testing

Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma

Who this might be right for
Leukemia, B-cellLymphoma, B-Cell
Children's Hospital Medical Center, Cincinnati
Very early researchUnknownNCT06393335
What this trial is testing

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research

Who this might be right for
Acute Lymphoblastic LeukemiaNon-hodgkin Lymphoma
The Children's Hospital of Zhejiang University School of Medicine 36
Testing effectiveness (Phase 2)Study completedNCT03289455
What this trial is testing

CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL)

Who this might be right for
B Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Lymphoblastic LeukemiaRefractory Childhood Acute Lymphoblastic Leukemia+1 more
Autolus Limited 23
Not applicableNot Yet RecruitingNCT07637929
What this trial is testing

Non-Interventional Study of Puzol-cel for CD19-Positive Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Who this might be right for
Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (r/r B-ALL)
Chongqing Precision Biotech Co., Ltd 200
Early research (Phase 1)Ended earlyNCT03593109
What this trial is testing

A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell Lymphoma

Who this might be right for
Lymphoma, B-Cell
Second Affiliated Hospital of Xi'an Jiaotong University 1
Early research (Phase 1)Study completedNCT05563545
What this trial is testing

Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia

Who this might be right for
Acute Lymphoblastic Leukemia
Shanghai Simnova Biotechnology Co.,Ltd. 2
Testing effectiveness (Phase 2)Study completedNCT01865617
What this trial is testing

Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia

Who this might be right for
CD19-Positive Neoplastic Cells PresentRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Chronic Lymphocytic Leukemia+10 more
Fred Hutchinson Cancer Center 204
Very early researchStudy completedNCT04689204
What this trial is testing

CTA30X Cell Injection in Patients With Relapsed or Refractory CD19-positive B-line Hematological Malignancies

Who this might be right for
Acute Lymphoblastic LeukemiaNon-hodgkin Lymphoma
He Huang 3
Early research (Phase 1)UnknownNCT04037566
What this trial is testing

CRISPR (HPK1) Edited CD19-specific CAR-T Cells (XYF19 CAR-T Cells) for CD19+ Leukemia or Lymphoma.

Who this might be right for
Leukemia Lymphocytic Acute (ALL) in RelapseLeukemia Lymphocytic Acute (All) RefractoryLymphoma, B-Cell+1 more
Xijing Hospital 40
Early research (Phase 1)UnknownNCT04943016
What this trial is testing

CD19 CAR T Cells in Children and Adults With Relapsed or Refractory CD19 Positive B Cell Malignancies

Who this might be right for
Relapsed/Refractory B-Cell Malignancies
National Taiwan University Hospital 12
Early research (Phase 1)Not Yet RecruitingNCT07043218
What this trial is testing

A Clinical Study Exploring Universal CAR-T Cell in Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Who this might be right for
B-cell Acute Lymphoblastic Leukemia
Shanghai Tongji Hospital, Tongji University School of Medicine 36
Early research (Phase 1)Looking for participantsNCT06047197
What this trial is testing

Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma

Who this might be right for
Recurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-cell Lymphoma
Beijing Yongtai Ruike Biotechnology Company Ltd 25
Not applicableLooking for participantsNCT06866873
What this trial is testing

CD-19 CAR-T Cell for Pediatric ALL or Lymphoma

Who this might be right for
Lymphoma, B-CellAcute Lymphoblastic Leukemia, Pediatric
Hong Kong Children's Hospital 18
Early research (Phase 1)Looking for participantsNCT06287528
What this trial is testing

19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)

Who this might be right for
Philadelphia-Negative ALLPhiladelphia-Positive ALLRelapsed ALL, Adult+3 more
Memorial Sloan Kettering Cancer Center 18
Early research (Phase 1)Looking for participantsNCT05705570
What this trial is testing

Clinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies

Who this might be right for
Acute Lymphoblastic Leukemia, in RelapseAcute Lymphoblastic Leukemia RefractoryB-cell Lymphoma Recurrent+3 more
Nelson Hamerschlak 30
Very early researchUnknownNCT04011293
What this trial is testing

A Clinical Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Injection (CNCT19) in the Treatment of Cluster of Differentiation 19 (CD19) Positive Relapsed or Refractory B Cell Malignancies

Who this might be right for
Relapsed or Refractory Hematological Malignancies
Shandong University 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT04404660
What this trial is testing

CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

Who this might be right for
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
Autolus Limited 153
Testing effectiveness (Phase 2)UnknownNCT02819583
What this trial is testing

CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

Who this might be right for
Acute Lymphocytic LeukemiaChronic Lymphocytic LeukemiaFollicular Lymphoma+3 more
PersonGen BioTherapeutics (Suzhou) Co., Ltd. 10
Testing effectiveness (Phase 2)UnknownNCT02851589
What this trial is testing

Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

Who this might be right for
Acute Lymphocytic LeukemiaChronic Lymphocytic LeukemiaFollicular Lymphoma+3 more
PersonGen BioTherapeutics (Suzhou) Co., Ltd. 10
Load More Results